This fact can explain RCC's high resistance to conventional chemo- and radiotherapy, and the absence of Bcl-2 had a positive predictive value for the response to immunotherapy in metastatic RCC, as was disclosed in our recent study (Maruyama et al, 2006). This evidence concerns the gene BCL2 and renal cell adenocarcinoma.